Asunto(s)
Medios de Contraste , Sistemas de Liberación de Medicamentos , Fluorocarburos , Ultrasonografía , Animales , Medios de Contraste/administración & dosificación , Dexametasona/administración & dosificación , Fluorocarburos/administración & dosificación , Ratones , Ratones Endogámicos BALB C , Compuestos Orgánicos , Profármacos/administración & dosificaciónAsunto(s)
Medios de Contraste , Membrana Dobles de Lípidos , Ultrasonografía , Animales , Medios de Contraste/toxicidad , Ecocardiografía , Gases , Membrana Dobles de Lípidos/toxicidad , Liposomas , Ratones , Ratones Endogámicos BALB C , Infarto del Miocardio/diagnóstico por imagen , Tamaño de la Partícula , Conejos , PorcinosRESUMEN
Liposomes with a mean diameter of 1-2 microns were made to entrap nitrogen gas and tested as an ultrasound (US) contrast agent. The gas-filled liposomes, or Aerosomes (ImaRx Pharmaceutical, Tucson) were tested in vitro for size, stability, reflectivity, and acoustic characterization, and were tested in vivo for acute toxicity in mice and for cardiac imaging in rabbits after intravenous injection. Aerosomes have much greater reflectivity and higher attenuation than do standard liposomes and retain their acoustic properties after storage in aqueous media for several months. The interpolated median lethal dose of Aerosomes is approximately 2.5 mmol of lipid per kilogram, and the imaging dose is under 5 mumol of lipid per kilogram, yielding a potential therapeutic index of over 500 to 1. Postcontrast US images showed sustained enhancement of all four cardiac chambers as well as enhancement in the aorta, vena cava, and hepatic veins. Aerosomes hold promise as a contrast agent for cardiac and blood-pool imaging. Further work is in progress to characterize and develop this novel US contrast agent.